FDA Women’s Health Policy Is Target Of Reform Legislation From Rep. DeLauro
This article was originally published in The Pink Sheet Daily
Bill would re-elevate the Office of Women’s Health back to commissioner level, as well as require the agency to assess breast implant components and convene a workshop on Plan B.
You may also be interested in...
Behind-the-counter, dual status approval breaks the hold on commissioner nominee von Eschenbach.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.